Medical and Drug Policies
search

Member Policies - Medical Policies - Alabama

Policies & Guidelines
  • Autism Spectrum Mandate
  • Behavioral Health
  • Blue Advantage Policies
    • Medical Policies - Blue Advantage
      • Draft Policies
      • Final Policies: A - E
      • Final Policies: F - J
      • Final Policies: K - N
      • Final Policies: O - S
      • Final Policies: T - Z
    • PET, MRI, MRA, CT, CTA/CCTA
      • Draft Policies
    • Provider-Administered Drug Policies (Excluding Oncology)
      • Draft Provider-Administered Drug Policies
      • Final Provider-Administered Drug Policies (Excluding Oncology)
    • Provider-Administered Oncology Drug Policies
      • Draft Provider-Administered Oncology Drug Policies
      • Final Provider-Administered Oncology Drug Policies
    • Radiation Therapy Management (RTM)
      • Draft Policies
  • Chronic Condition Management
  • Hemophilia Drug Management
    • Draft Hemophilia Drug Policies
    • Final Hemophilia Drug Policies
    • Hemophilia Drug Pilot - PEEHIP Only
    • Hemophilia Drug Prior Authorization
  • Medical Policies
    • Draft Medical Policies
    • Final Medical Policies
      • Administrative
      • DME
      • Laboratory
      • Medical
      • OB/GYN
      • Other
      • Pharmacology
      • Radiology
      • Supplies
      • Surgical
      • Therapy
      • Vision
  • PET, MRI, MRA, CT, CTA/CCTA
    • Draft Policies
  • Provider-Administered Drug Policies (Excluding Oncology)
    • Draft Provider-Administered Drug Policies
    • Final Provider-Administered Drug Policies
    • Provider-Administered Drug Forms
    • Voluntary Site of Service
  • Provider-Administered Oncology Drug Policies
    • Draft Provider-Administered Oncology Drug Policies
    • Final Provider-Administered Oncology Drug Policies
  • Radiation Therapy Management (RTM)
    • Draft Policies
  • Self-Administered Drug Policies
    • Draft Self-Administered Drug Policies
    • Final Self-Administered Drug Policies
    • Self-Administered Drug Forms
  • Transgender Services
Policy # Policy Title View
BA-650 Abraxane (paclitaxel, protein-bound)
BA-651 Adcetris® (brentuximab vedotin) - Blue Advantage
BA-652 Alimta (pemetrexed disodium)
BA-653 Arzerra (ofatumumab) and Gazyva (obinutuzumab) - Blue Advantage
BA-672 Bavencio® (avelumab)
BA-669 Bendeka and Treanda (bendamustine hydrochloride)
BA-678 Besponsa (inotuzumab ozogamicin)
BA-655 Cyramza (ramucirumab) - Blue Advantage
BA-670 Darzalex® (daratumumab)
BA-671 Empliciti (Elotuzumab)
BA-656 Erbitux (cetuximab)
BA-673 Imfinzi (durvalumab)
BA-658 Kadcyla® (ado-trastuzumab emtansine) - Blue Advantage
BA-666 Keytruda (pembrolizumab) - Blue Advantage
BA-675 Kymriah (tisagenlecleucel)
BA-659 Kyprolis (Carfilzomib injection) - Blue Advantage
BA-677 Lartruvo (olaratumab)
BA-679 Mylotarg (gemtuzumab ozogamicin)
BA-660 Opdivo® (nivolumab) - Blue Advantage
BA-661 Perjeta® (pertuzumab) - Blue Advantage
BA-668 Tecentriq™ (Atezolizumab) - Blue Advantage
BA-664 Vectibix® (panitumumab) - Blue Advantage
BA-667 Yervoy (ipilimumab) - Blue Advantage
BA-676 Yescarta (axicabtagene ciloleucel)
BA-665 Zaltrap® (ziv-aflibercept) - Blue Advantage
Node: bclrgrpappp2001.corp.bcbsal.org:8080

CPT codes, descriptions and data copyright ©BCBSPREVIOUSYEAR American Medical Association. All rights reserved. Applicable FARS/DFARS apply. 
CDT codes, descriptions and data copyright ©BCBSPREVIOUSYEAR American Dental Association. All rights reserved.

© BCBSCURRENTYEAR Blue Cross and Blue Shield of Alabama is an independent licensee of the Blue Cross and Blue Shield Association.